Literature DB >> 24474514

Statins and neuroprotection: basic pharmacology needed.

W Gibson Wood1, Walter E Mΰller, Gunter P Eckert.   

Abstract

Statins are attracting great interest albeit with some controversy in treating certain neurodegenerative diseases such as Alzheimer disease, Parkinson disease, multiple sclerosis, ischemic stroke, and traumatic brain injury. Support for the use of statins has come from human studies and animal and cell models. Despite the intense level of interest, there is a deficiency in information on the basic pharmacokinetics and pharmacodynamics of statins in the brain. The purpose of this focused review is to examine what is known and the gaps in our knowledge on detectability of statin lactones and acids in the brain, membrane partitioning and active transport of statins across the blood-brain barrier, and statin effects on brain isoprenoid levels. Statins may be efficacious in treating certain neurodegenerative diseases. Having basic information on statin pharmacokinetics and pharmacodynamics in the brain would provide insight into specific drug targets and also provide the rationale for optimizing statins in terms of enhancing brain influx and inhibiting efflux.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24474514     DOI: 10.1007/s12035-014-8647-3

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  62 in total

Review 1.  Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations.

Authors:  G Lee; S Dallas; M Hong; R Bendayan
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 25.468

2.  Inhibitory effects of statins on human monocarboxylate transporter 4.

Authors:  Masaki Kobayashi; Yukio Otsuka; Shirou Itagaki; Takeshi Hirano; Ken Iseki
Journal:  Int J Pharm       Date:  2006-04-18       Impact factor: 5.875

3.  Mammalian carboxylesterase 3: comparative genomics and proteomics.

Authors:  Roger S Holmes; Laura A Cox; John L VandeBerg
Journal:  Genetica       Date:  2010-04-28       Impact factor: 1.082

Review 4.  Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies.

Authors:  David J Loane; Alan I Faden
Journal:  Trends Pharmacol Sci       Date:  2010-10-29       Impact factor: 14.819

Review 5.  Diverse effects of statins on angiogenesis: new therapeutic avenues.

Authors:  Hazem F Elewa; Azza B El-Remessy; Payaningal R Somanath; Susan C Fagan
Journal:  Pharmacotherapy       Date:  2010-02       Impact factor: 4.705

6.  Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin.

Authors:  Karin M Thelen; Katharina M Rentsch; Ursula Gutteck; Maura Heverin; Maria Olin; Ulla Andersson; Arnold von Eckardstein; Ingemar Björkhem; Dieter Lütjohann
Journal:  J Pharmacol Exp Ther       Date:  2005-11-10       Impact factor: 4.030

Review 7.  Statins: multiple neuroprotective mechanisms in neurodegenerative diseases.

Authors:  Qing Wang; Junqiang Yan; Xiaohong Chen; Jin Li; Yu Yang; Jianping Weng; Chao Deng; Midori A Yenari
Journal:  Exp Neurol       Date:  2010-04-18       Impact factor: 5.330

8.  Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment.

Authors:  Cornelia Franke; Michael Nöldner; Reham Abdel-Kader; Leslie N Johnson-Anuna; W Gibson Wood; Walter E Müller; Gunter P Eckert
Journal:  Neurobiol Dis       Date:  2006-12-06       Impact factor: 5.996

9.  A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.

Authors:  B Hsiang; Y Zhu; Z Wang; Y Wu; V Sasseville; W P Yang; T G Kirchgessner
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

10.  Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth.

Authors:  Kovi Bessoff; Adam Sateriale; K Kyungae Lee; Christopher D Huston
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

View more
  15 in total

Review 1.  Oxidative stress as a possible mechanism of statin-induced myopathy.

Authors:  Yasin Ahmadi; Amir Ghorbanihaghjo; Mohsen Naghi-Zadeh; Neda Lotfi Yagin
Journal:  Inflammopharmacology       Date:  2018-03-24       Impact factor: 4.473

2.  Neuroprotective effects of lovastatin in the pilocarpine rat model of epilepsy according to the expression of neurotrophic factors.

Authors:  Pooyan Moradi; Mahin Ganjkhani; Iraj Jafari Anarkooli; Alireza Abdanipour
Journal:  Metab Brain Dis       Date:  2019-05-29       Impact factor: 3.584

3.  Statins and Gliomas: A Systematic Review of the Preclinical Studies and Meta-Analysis of the Clinical Literature.

Authors:  Luis F Rendon; Ishaan A Tewarie; David J Cote; Aaron Gabriel; Timothy R Smith; Marike L D Broekman; Rania A Mekary
Journal:  Drugs       Date:  2022-02-05       Impact factor: 9.546

Review 4.  Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer's disease.

Authors:  Angela Jeong; Kiall Francis Suazo; W Gibson Wood; Mark D Distefano; Ling Li
Journal:  Crit Rev Biochem Mol Biol       Date:  2018-06       Impact factor: 8.250

5.  Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress.

Authors:  Camille B Carroll; Richard K H Wyse
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

6.  Protective effects of coenzyme Q10 and L-carnitine against statin-induced pancreatic mitochondrial toxicity in rats.

Authors:  Melina Sadighara; Jalal Pourahamad Joktaji; Valiollah Hajhashemi; Mohsen Minaiyan
Journal:  Res Pharm Sci       Date:  2017-12

Review 7.  Human isoprenoid synthase enzymes as therapeutic targets.

Authors:  Jaeok Park; Alexios N Matralis; Albert M Berghuis; Youla S Tsantrizos
Journal:  Front Chem       Date:  2014-07-22       Impact factor: 5.221

Review 8.  Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders.

Authors:  K Gottlieb; V Wacher; J Sliman; M Pimentel
Journal:  Aliment Pharmacol Ther       Date:  2015-11-11       Impact factor: 8.171

9.  Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway.

Authors:  Steven M Muskal; Joe Sliman; John Kokai-Kun; Mark Pimentel; Vince Wacher; Klaus Gottlieb
Journal:  F1000Res       Date:  2016-04-08

Review 10.  The renin-angiotensin system: a possible new target for depression.

Authors:  João Vian; Círia Pereira; Victor Chavarria; Cristiano Köhler; Brendon Stubbs; João Quevedo; Sung-Wan Kim; André F Carvalho; Michael Berk; Brisa S Fernandes
Journal:  BMC Med       Date:  2017-08-01       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.